Given the fact that DNA damage response was the most prominent function identified in the functional annotation analyses and that the PARP inhibitor olaparib is approved in breast cancer, we decided to explore the effect of the combination of dasatinib with this agent in TNBC cell lines (MDA‐MB‐231, HS‐578T, BT549 and HCC3153). This evidence concerns the gene PARP1 and breast carcinoma.